Raltegravir Potassium Salt

Category	HIV Integrase
CAS	871038-72-1
Description	Raltegravir is a potent, selective, and orally bioavailable inhibitor of HIV integrase (IC50 = 15 nM). It is metabolized primarily by uridine diphosphate glucuronosyltransferase 1A. Raltegravir has long-term efficacy and safety in managing HIV-1 infection in adults, children, and adolescents.

Quotation Now

Product Information

Synonyms	MK-0518; MK 0518; MK0518; Raltegravir
IUPAC Name	potassium;4-[(4-fluorophenyl)methylcarbamoyl]-1-methyl-2-[2-[(5-methyl-1,3,4-oxadiazole-2-carbonyl)amino]propan-2-yl]-6-oxopyrimidin-5-olate
Molecular Weight	482.514
Molecular Formula	C20H20FKN6O5
Canonical SMILES	CC1=NN=C(O1)C(=O)NC(C)(C)C2=NC(=C(C(=O)N2C)[O-])C(=O)NCC3=CC=C(C=C3)F.[K+]
InChI	InChI=1S/C20H21FN6O5.K/c1-10-25-26-17(32-10)16(30)24-20(2,3)19-23-13(14(28)18(31)27(19)4)15(29)22-9-11-5-7-12(21)8-6-11;/h5-8,28H,9H2,1-4H3,(H,22,29)(H,24,30);/q;+1/p-1
InChIKey	IFUKBHBISRAZTF-UHFFFAOYSA-M
Melting Point	155-157°C (dec.)
Purity	98%
Density	1.46 g/cm3
Solubility	In Vitro: H2O: 25 mg/mL (51.81 mM; Need ultrasonic) DMSO : 6 mg/mL (12.43 mM; Need ultrasonic) In Vivo: 1.Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 0.6 mg/mL (1.24 mM); Clear solution 2.Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 0.6 mg/mL (1.24 mM); Clear solution 3.Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 0.6 mg/mL (1.24 mM); Clear solution
Appearance	White crystalline powder
Application	Anti-HIV Agents
Storage	Powder: -20°C: 3 years 4°C: 2 years In solvent: -80°C: 6 months -20°C: 1 month
Complexity	843
Exact Mass	482.11162741
In Vitro	PFV IN carrying the S217H substitution is 10-fold less susceptible to Raltegravir with IC50 of 900 nM. PFV IN displays 10% of WT activity and is inhibited by Raltegravir with an IC50 of 200 nM, indicating a appr twofold decrease in susceptibility to the IN strand transfer inhibitor (INSTI) compared with WT IN. Raltegravir has potent in vitro activity against HIV-1, with a 95% inhibitory concentration of 31±20 nM, in human T lymphoid cell cultures. Raltegravir is also active against HIV-2 when Raltegravir is tested in CEM x 174 cells, with an IC95 of 6 nM. Raltegravir exhibits weak inhibitory effects on hepatic cytochrome P450 activity. In acutely infected human lymphoid CD4+ T-cell lines MT-4 and CEM x 174, SIVmac251 replication is efficiently inhibited by Raltegravir, which shows an EC90 in the low nanomolar range.
In Vivo	Raltegravir induces viro-immunological improvement of nonhuman primates with progressing SIVmac251 infection. One non-human primate shows an undetectable viral load following Raltegravir monotherapy.
PSA	155.07000
Target	HIV Integrase; HIV